Our findings suggest that treatment with apigenin decreases the protein levels of fetuin-A and p-fetuin-A, prevents the formation of the fetuin-A-IR complex, and improves glucose utilization, consequently attenuating the insulin resistance induced by PA or obesity. The gene discussed is AHSG; the disease is obesity due to melanocortin 4 receptor deficiency.